2025版《中国肿瘤整合诊治指南（CACA）—甲状腺癌》系统解读

Systematic interpretation of the 2025 Chinese Guidelines for Integrated Diagnosis and Treatment of Tumors (CACA) — Thyroid Cancer

摘要:

甲状腺癌是近年来发病率增长最快的恶性肿瘤之一，中国患者的5年相对生存率也显著提升。精准诊断、规范治疗及有效随访是提高疗效的关键环节，临床指南的推广应用则是实现规范化和同质化管理的重要保障。中国抗癌协会（CACA）于2022年发布2022版《中国肿瘤整合诊治指南（CACA）—甲状腺癌》，首次将多学科整合诊疗理念系统应用于甲状腺癌的全程管理，体现了中国特色与本土经验。2025年，CACA在此基础上结合最新循证证据和临床实践，对指南进行了更新修订，形成该指南的2025版。本文系统解读该指南在甲状腺癌的诊断、治疗及随访方面的主要内容，旨在为临床医师提供操作性强的实践参考，进一步规范甲状腺癌的整合诊治管理。

Abstract:

Thyroid cancer has become one of the fastest-growing malignancies in recent years, with a significant improvement in the 5-year relative survival rate among Chinese patients. Accurate diagnosis, standardized treatment, and effective follow-up are essential to improve clinical outcomes, while the promotion and implementation of clinical guidelines are critical for achieving standardized and homogeneous management. In 2022, the China Anti-Cancer Association (CACA) released the 2022 Chinese Guidelines for Integrated Diagnosis and Treatment of Tumors (CACA) — Thyroid Cancer, which systematically applied the concept of multidisciplinary integrated management to the entire care continuum of thyroid cancer, reflecting both Chinese characteristics and local experience. Building upon this, the 2025 edition of the guidelines was updated and revised based on the latest evidence and clinical practices. This article provides a systematic interpretation of the 2025 CACA guidelines, focusing on the diagnosis, treatment, and follow-up of thyroid cancer, with the aim of offering practical guidance for clinicians and promoting standardized, integrated management of thyroid cancer in clinical practice.